A359090 Stock Overview
No business description. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
C&R Research Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩1,120.00 |
52 Week High | ₩2,395.00 |
52 Week Low | ₩980.00 |
Beta | 0.18 |
11 Month Change | -9.68% |
3 Month Change | -7.44% |
1 Year Change | -5.88% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -55.91% |
Recent News & Updates
Shareholder Returns
A359090 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | 12.0% | -2.3% | 2.3% |
1Y | -5.9% | 34.0% | -3.8% |
Return vs Industry: A359090 underperformed the KR Life Sciences industry which returned 34% over the past year.
Return vs Market: A359090 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
A359090 volatility | |
---|---|
A359090 Average Weekly Movement | 6.8% |
Life Sciences Industry Average Movement | 8.8% |
Market Average Movement | 5.7% |
10% most volatile stocks in KR Market | 11.4% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A359090 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A359090's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 495 | Moontae Yoon | www.cnrres.com |
C&R Research Inc. Fundamentals Summary
A359090 fundamental statistics | |
---|---|
Market cap | ₩63.53b |
Earnings (TTM) | ₩5.15b |
Revenue (TTM) | ₩58.40b |
12.3x
P/E Ratio1.1x
P/S RatioIs A359090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A359090 income statement (TTM) | |
---|---|
Revenue | ₩58.40b |
Cost of Revenue | ₩0 |
Gross Profit | ₩58.40b |
Other Expenses | ₩53.25b |
Earnings | ₩5.15b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 90.75 |
Gross Margin | 100.00% |
Net Profit Margin | 8.81% |
Debt/Equity Ratio | 11.1% |
How did A359090 perform over the long term?
See historical performance and comparison